▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #249 by analyst upside · 2026-08-14
TVRD
Tvardi Therapeutics, Inc.
Healthcare · Market Cap $22M · P/E 0x
ANALYST PRICE TARGET
+380.2%
implied upside to consensus target
Current Price $1.77
Consensus Target $8.5
Bull Target $13.0
Bear Target $3.0
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
4
Hold
1
Sell
1
52-Week Low $1.5
52-Week High $43.65
YTD Return -56.6%
FUNDAMENTALS
Market Cap $22M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.27
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.5
52-Week High $43.65
Current Price $1.77
Bear Target $3.0
Bull Target $13.0
● Now $1.77 ● Target $8.5
TRADING DATA
Avg Volume 2.4M
YTD Return -56.6%
Analyst Count 8
Consensus Buy
Upside to Target +380.2%
Last Updated 2026-08-14

ANALYST SUMMARY

Tvardi Therapeutics, Inc. (TVRD) is currently trading at $1.77 with a Wall Street consensus price target of $8.5, implying potential upside of 380.2% over the next 12 months. 8 analysts currently cover TVRD, with a consensus rating of Buy - 75% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $13.0, while the most cautious has a target of $3.0.

TVRD operates in the Healthcare sector with a market capitalisation of $22M. The stock is down 56.6% year-to-date and is currently trading near the lower end of its 52-week range of $1.5 – $43.65.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ATNM +418.7%
Actinium Pharmaceuticals, Inc.
$30M · P/E 2.4x · Buy
PTN +435.0%
Palatin Technologies, Inc.
$18M · P/E 83.3x · Buy
YCBD +254.0%
cbdMD, Inc.
$6M · P/E 0.2x · Strong Buy
FBIO +269.1%
Fortress Biotech, Inc.
$99M · P/E 0.9x · Buy
SPRO +222.6%
Spero Therapeutics, Inc.
$72M · P/E 4.4x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for TVRD, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. ● Initiated
Buy 2026-06-08 31% win rate (48 calls)
Barclays ↓ Downgrade
Equal-Weight → Underweight 2026-04-20 Building track record
Barclays - Reiterated
Equal-Weight → Equal-Weight 2026-04-01 Building track record
Piper Sandler - Reiterated
Neutral → Neutral 2026-04-01 14% win rate (7 calls)
BTIG reit
Buy → Buy 2026-04-01 38% win rate (8 calls)
Raymond James ↓ Downgrade
Outperform → Market Perform 2025-10-14 Building track record
BTIG - Reiterated
Buy → Buy 2025-10-13 38% win rate (8 calls)
Barclays ● Initiated
Overweight 2025-10-13 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
31
out of 100
Coverage depth
17/30
Consensus clarity
0/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →